AM-Pharma Holding B.V.

Based in the Netherlands, AM-Pharma Holding B. V. focuses on developing innovative therapeutics for severe medical conditions, particularly in support of cardiac surgery patients and those with rare diseases like hypophosphatasia. AM-Pharma Holding B.

V. develops therapeutics for severe medical conditions, emphasizing cardiac surgery-associated renal damage and hypophosphatasia. Established in 2000 and headquartered in Utrecht, Netherlands, the company has completed 12 deals to date. Juliane Bernholz serves as the CEO.

AM-Pharma specializes in the development of therapeutics aimed at treating severe medical conditions, primarily focusing on cardiac surgery-associated renal damage (CSA-RD) and hypophosphatasia (HPP). Their flagship product, ilofotase alfa, is a proprietary compound designed to offer reno-protective effects for patients undergoing cardiac surgeries, addressing a significant complication that occurs in approximately 40% of such surgeries. The compound has demonstrated a proven safety profile and has been evaluated in global clinical trials with over 1,000 subjects. Additionally, AM-Pharma is advancing ilofotase alfa as a potential enzyme replacement therapy for HPP, an orphan disease characterized by impaired bone mineralization.

This product is positioned to serve healthcare providers and patients in various markets, including North America and Europe, where the need for innovative treatments for these serious conditions is critical. AM-Pharma generates revenue through the development and potential commercialization of its therapeutic products, specifically ilofotase alfa. The company engages in business-to-business transactions primarily with healthcare institutions and specialized medical providers involved in cardiac surgery and the treatment of rare diseases. These transactions may include partnerships with hospitals for clinical trials and future sales of ilofotase alfa upon regulatory approval.

The revenue model is structured around direct sales to healthcare providers, which would be initiated upon the successful launch of products in relevant markets. Given its classification of ilofotase alfa as an orphan drug, it is anticipated that the company may leverage incentives such as market exclusivity and accelerated approval pathways to enhance revenue potential, aligning with their strategic focus on addressing unmet medical needs in acute and chronic kidney injury management. AM-Pharma Holding B. V.

aims to expand its product offerings, particularly with the continued development of ilofotase alfa for both cardiac surgery-associated renal damage and hypophosphatasia. The company is also planning to extend its reach into new markets, targeting regions in North America and Europe by 2025. Recent funding of EUR 23. 00 mn raised from investors, including Andera Partners and EQT Life Sciences, will support these initiatives, focusing on clinical trials and marketing efforts to facilitate the launch of their key therapeutic product.